WANY
KRYS icon

Wealthspire Advisors (New York)’s Krystal Biotech KRYS Stock Holding History

Wealthspire Advisors (New York)’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15
Closed -$2.65K – 2030
2025
Q3 		$2.65K Buy
+15
New +$2.25K ﹤0.01% 2527

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealthspire Advisors (New York)'s KRYS Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Krystal Biotech (KRYS) in Q4 2025, closing a stake of 15 shares — an estimated $2.65K sold.

Wealthspire Advisors (New York) first reported a position in KRYS in Q3 2025 and held it in 1 quarter. The position peaked at $2.65K in Q3 2025. 334 funds tracked by Wall St. Rank hold KRYS as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Krystal Biotech position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 15 Krystal Biotech shares in Q4 2025, an estimated $2.65K.
  • Wealthspire Advisors (New York) first reported a position in Krystal Biotech in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Krystal Biotech position peaked at $2.65K in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.